Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform
Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has raised $30 million in new funding. This follows Prokarium’s announcement of partnering with Ginkgo Bioworks to leverage its world-class Foundry and extensive Codebase to develop a bactofection platform technology.
“We are excited to advance our vision to create living cures,” said Kristen Albright, PharmD, Chief Executive Officer of Prokarium. “Proceeds of this financing will fund our lead oncology program entering clinical development this year and enable platform expansion for the delivery of novel therapeutic payloads, including RNA, via our proprietary bacteria. With Ginkgo’s partnership and their expertise in strain engineering and optimization we look forward to working towards unlocking a new generation of immuno-oncology therapeutics.”
Prokarium’s lead program has the potential to transform the treatment paradigm in bladder cancer, one of the costliest cancers to treat, in its efforts to become the new standard-of-care in a market that has seen little innovation in over 30 years and to offer advanced therapies an alternative to Bacillus Calmette-Guérin (BCG). Prokarium’s pipeline leverages evolutionary advantages of a proprietary strain of Salmonella and combines them with bespoke synthetic circuits to deliver diverse therapeutic cargo for difficult-to-treat cancers.
“We believe Prokarium is a truly differentiated company,” added Thomas Eldered, Executive Chairman, Flerie Invest. “The new funds and Prokarium’s partnership with Ginkgo Bioworks will accelerate the cutting-edge innovation essential to lead the advancements in the field of synthetic biology and immunotherapy for years to come.”
“Our partnership with Prokarium will utilize Ginkgo’s leading platform capabilities and services to pioneer technological developments that we believe will revolutionize the immuno-oncology field,” added Ena Cratsenburg, Chief Business Officer at Ginkgo Bioworks. “Ginkgo is excited to partner with Prokarium to work to build a versatile Salmonella-based bactofection platform capable of delivering targeted, localized RNA therapeutics.”
In addition to the financing, Prokarium has announced the addition of two scientific advisors, Professor Adrian Hayday, PhD and Sam Chang, MD, MBA. “We are thrilled to welcome Adrian and Sam as advisors as we transition into a clinical-stage company,” concluded Albright. “Adrian brings the deep immunology and immunotherapy expertise, and Sam possesses invaluable clinical experience being involved in numerous bladder cancer clinical trials.” Professor Hayday is the founding Chair of Peter Gorer Department of Immunobiology at King’s College London and is currently Principal Group Leader at the Francis Crick Institute. Sam currently serves as the Chief Surgical Officer at the Vanderbilt Ingram Cancer Center.
About Prokarium
Prokarium is a biopharmaceutical company leading the oncology field of microbial immunotherapy with the vision to create living cures. The Company’s pipeline is designed to unlock a new generation of immuno-oncology therapeutics by re-engineering evolution into a synthetic biology platform. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based in London, UK. For further information, visit www.prokarium.com.
About Flerie Invest
Flerie Invest is an active long-term global biotech and pharma investor based in Stockholm and London managing a portfolio of over 30 companies in Europe, Israel and the US. The focus is on enabling pioneering organisations operating in the drug development and services space to succeed by providing them with resources and expertise. The portfolio includes a wide range of areas including immuno- oncology, metabolic diseases and biologics development and manufacturing organisations which have the potential to make a significant impact in health and wellbeing. Flerie Invest was founded in 2011 by Thomas Eldered, who also co-founded and built Recipharm to be one of the world’s top five pharmaceutical contract manufacturers. For more information, please visit www.flerie.com.
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo’s biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as Twitter (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), or LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230209005006/en/
Contact information
PROKARIUM CONTACT:
Lisa Stone
lisa.stone@prokarium.com
GINKGO BIOWORKS CONTACT:
press@ginkgobioworks.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OMRON Releases the “Medium-Term Roadmap SF 2nd Stage”8.11.2025 08:00:00 EET | Press release
OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November 7, 2025 (JST). This Roadmap presents the Group’s vision and growth strategies through 2030, which are disclosed on our corporate website. Overview of the “Medium-Term Roadmap SF 2nd Stage” Since April 2024, OMRON has been implementing a Structural Reform Program “NEXT 2025” aimed at rebuilding our foundation for profitability and growth. With the completion of this Program in September 2025, we have shifted into a growth phase and formulated a new Roadmap looking ahead to 2030. This Roadmap identifies Business Portfolio Restructuring as a core strategy. We have defined Thirteen Focus Businesses to drive the Group’s future growth. By accelerating our selection and concentration efforts, we aim to build a “distinctive” business portfolio that maximizes overall Group growth. Furthermore, to maximize the growth potential of our Focus Busines
26 th UN Tourism General Assembly kicks off in Riyadh7.11.2025 23:13:00 EET | Press release
The 26th session of the UN Tourism General Assembly opened today in Riyadh, marking a historic first for the Gulf Cooperation Council (GCC) region and the largest Assembly since UN Tourism was founded 50 years ago. Around 160 delegations from member states including ministers, senior officials, and leaders from across industry and civil society are coming together to celebrate five decades of international collaboration under the theme “AI-Powered Tourism: Redefining the Future.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107012471/en/ 26th UN Tourism General Assembly kicks off in Riyadh The Assembly is hosted by Saudi Arabia’s Ministry of Tourism, with extensive cooperation and planning alongside UN Tourism and a wide range of partners. This collaboration underscores the Kingdom’s dedication to advancing the industry and facilitating impactful dialogue on the global stage. For half a century, UN Tourism has advanced
Xsolla Partners With Deloitte Turkiye and Lorien Accelerator as Category Sponsor for Gaming Awards at Fast 50 Türkiye 2025 Program7.11.2025 20:11:00 EET | Press release
Xsolla, a leading global video game commerce company that helps developers launch, grow, and monetize their games, is proud to announce its sponsorship of the Gaming Awards segment at the Deloitte Technology Fast 50 Türkiye 2025 Program, organized in collaboration with Lorien Accelerator. The event will take place on December 10, 2025, and will recognize Turkey’s top high-growth companies across various industries, with a special focus on the dynamic gaming sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107671030/en/ Graphic: Xsolla As the Gaming Awards category sponsor, Xsolla will receive significant brand exposure through prominent logo placements across all event materials, including digital platforms, official event signage, and other promotional materials. In addition to this visibility, Xsolla’s participation includes an exclusive opportunity to engage in a panel discussion focused on Turkey’s rapidly growi
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy7.11.2025 18:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The results were presented at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston. IgA nephropathy is a lifelong progressive autoimmune disease often diagnosed in young people aged 10-30 years old that causes irreversible damage to the kidney function.2 It has no cure, and despite available treatments, approximately one in five patients experience renal failure within 10 years of diagnosis.3 By depleting cells that produce an abnormal protein called Gd-IgA1 implicated in the pathogenesis, mezagitamab targets early steps in the process lea
Oremus Corporate Services Expands into Europe with Launch in Finland7.11.2025 17:23:00 EET | Press release
Oremus Corporate Services Private Limited, a multinational Finance and Accounting Advisory firm having its offices in the USA, India and the UK, has announced the extension of its services to Finland, marking the company’s foray into the European market. With over two decades of expertise in accounting, payroll, tax compliance, and advisory services, Oremus has earned trust as a technology-driven finance partner serving clients across geographies. Oremus is an ISAE 3402, ISO 27001, GDPR & DPDP Compliant Company, adhering to International Quality and Security Standards. “Finland isn’t just a new market for us — it’s the gateway to meaningful, growth-driven partnerships across Europe”. said Lalit Ananth Chawla, CEO of Oremus. Having established a strong reputation for delivering reliable Accounting and Advisory solutions to scale-ups and growing businesses, we seek to collaborate with like-minded firms and investors to build a trusted growth ecosystem. Our vision is to offer technology-d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom